Experimental Clinical Study Expected to Complete During the Fourth Quarter 2013
CAMBRIDGE, MA, USA I September 9, 2013 I Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013.
“Measuring Laser Evoked Potentials is an experimental clinical model that offers both subjective and objective measures to assess the potential of Z944 to modulate pain signaling,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “T-type calcium channels are known to be widely implicated in the frequency and intensity of pain signals and the results of this study will further inform Zalicus’ development plans for Z944 in a variety of potential indications as we work to optimize a modified release formulation of Z944 for future clinical trials.”
The LEP clinical model is a type of experimental medicine study designed to provide both objective and subjective data on a drug’s ability to modulate pain signaling. In this model electrical voltage fluctuations evoked by laser thermal stimulation are quantified with vertex-Electroencephalography (EEG) in addition to a subject-reported pain score. Many currently approved and emerging pain drugs have been evaluated using the LEP model, providing the ability to benchmark the efficacy of Z944 against other therapies.
About Z944 and T-type Calcium Channel Blockers
Z944 is a novel, oral, state-dependent, selective T-type calcium channel blocker that has demonstrated preclinical efficacy in multiple inflammatory pain models. T-type calcium channels have been recognized as key targets for therapeutic intervention in a broad range of cell functions and have been implicated in pain signaling. Zalicus has completed Phase 1 single and multiple ascending dose clinical studies evaluating the safety and tolerability of Z944 and is continuing the clinical development of Z944 during 2013.
About Zalicus
Zalicus Inc. (Nasdaq Capital Market:ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain such as Z160 and Z944 and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.
SOURCE: Zalicus
Post Views: 139
Experimental Clinical Study Expected to Complete During the Fourth Quarter 2013
CAMBRIDGE, MA, USA I September 9, 2013 I Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013.
“Measuring Laser Evoked Potentials is an experimental clinical model that offers both subjective and objective measures to assess the potential of Z944 to modulate pain signaling,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “T-type calcium channels are known to be widely implicated in the frequency and intensity of pain signals and the results of this study will further inform Zalicus’ development plans for Z944 in a variety of potential indications as we work to optimize a modified release formulation of Z944 for future clinical trials.”
The LEP clinical model is a type of experimental medicine study designed to provide both objective and subjective data on a drug’s ability to modulate pain signaling. In this model electrical voltage fluctuations evoked by laser thermal stimulation are quantified with vertex-Electroencephalography (EEG) in addition to a subject-reported pain score. Many currently approved and emerging pain drugs have been evaluated using the LEP model, providing the ability to benchmark the efficacy of Z944 against other therapies.
About Z944 and T-type Calcium Channel Blockers
Z944 is a novel, oral, state-dependent, selective T-type calcium channel blocker that has demonstrated preclinical efficacy in multiple inflammatory pain models. T-type calcium channels have been recognized as key targets for therapeutic intervention in a broad range of cell functions and have been implicated in pain signaling. Zalicus has completed Phase 1 single and multiple ascending dose clinical studies evaluating the safety and tolerability of Z944 and is continuing the clinical development of Z944 during 2013.
About Zalicus
Zalicus Inc. (Nasdaq Capital Market:ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain such as Z160 and Z944 and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.
SOURCE: Zalicus
Post Views: 139
